首页> 美国卫生研究院文献>Health Research Policy and Systems >From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries
【2h】

From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries

机译:从市场准入到患者准入:36个欧洲国家的药品报销和定价的循证方法概述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCoverage decisions determining the benefit baskets of health systems have been increasingly relying on evidence regarding patient benefit and costs. Relevant structures, methodologies, and processes have especially been established for pharmaceuticals but approaches differ. The objective of this work was thus to identify institutions in a broad range of European countries (n = 36) in charge of determining the value of pharmaceuticals for pricing and reimbursement purposes and to map their decision-making process; to examine the different approaches and consider national and supranational possibilities for best practice.
机译:背景技术确定卫生系统的福利篮子的覆盖范围决策越来越依赖于有关患者福利和成本的证据。已经为药物建立了相关的结构,方法和过程,但是方法有所不同。因此,这项工作的目的是确定欧洲许多国家(n = 36)的机构,这些机构负责确定用于定价和报销目的的药品价值,并绘制其决策程序;研究不同的方法,并考虑国家和超国家最佳实践的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号